Filing Analysis
📄 Other SEC Filing
Filed Jun 12, 2026
⚪ LOW
Nuvectis Pharma reported the results of its 2026 Annual Meeting held on June 11, 2026. All proposals, including the election of a Class I director and the ratification of the independent auditor, were approved.
🚩 Red Flags
- Inadvertent misstatement of total shares outstanding in the Definitive Proxy Statement filed on April 27, 2026.
📋 Key Facts
- Annual Meeting held on June 11, 2026, with a quorum of 60.8% (16,193,686 shares) present.
- Proposal 1: Ron Bentsur was elected as Class I director (8,354,838 votes For).
- Proposal 2: Kesselman & Kesselman was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2026 (15,662,222 votes For).
- The company corrected a previous misstatement in the Proxy Statement regarding shares outstanding: the correct number as of April 13, 2026, was 26,614,628, not 27,668,036.
📢 Regulation FD Disclosure
Filed May 05, 2026
⚪ LOW
Nuvectis Pharma, Inc. announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The information was furnished via a press release on May 5, 2026.
📋 Key Facts
- The filing reports financial results for the first quarter ended March 31, 2026
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- A press release containing the corporate update and financial results was furnished as Exhibit 99.1
- The report was signed by Chairman, CEO, and President Ron Bentsur
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.